Dermatological drug maker Journey Medical files for a $40 million IPO - (Renaissance Capital via NewsPoints Desk)

  • Dermatological drug developer Journey Medical filed on Friday with the US Securities and Exchange Commission to raise up to $40 million in an initial public offering, Renaissance Capital reported.

  • Journey Medical’s current portfolio includes five branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the US. 

  • Journey anticipates remaining a majority-owned subsidiary of Fortress Biotech.

To read more NewsPoints articles, click here.